Novartis Profit Beats Estimates, Signals Return to Growth
Novartis reported second-quarter core operating income of $5.94 billion, ahead of the $5.34 billion analyst consensus, on revenue of $14.41 billion, as newer cancer and MS drugs including Kisqali offset generic erosion of Entresto. It reaffirmed 2026 guidance, cautioning that one-off benefits would reverse as R&D and launch spending rises.
DeFi Intel is an entity-graph aggregator: we curate, tag and link crypto news to a typed knowledge graph of protocols, tokens, people and incidents. We do not republish the full article body. Use the link above to read the original report at Bloomberg_crypto.
Want the full article?
Continue reading on Bloomberg_crypto →